Ambrx Biopharma Appoints Edward Hu and Kate Hermans to its Board of Directors
05 Juli 2022 - 10:05PM
Business Wire
Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage
biopharmaceutical company using an expanded genetic code technology
platform to create Engineered Precision Biologics (EPBs), today
announced the appointments of Edward Hu and Kate Hermans to its
Board of Directors.
“I am delighted to welcome both Edward and Kate to Ambrx’s
Board,” said Feng Tian, Ph. D., Chairman of the Board, President,
and CEO of Ambrx. “Together, they have decades of experience in
business strategy and operations in the pharmaceutical industry on
a global scale. I look forward to working closely with Edward and
Kate and utilizing their invaluable insight as we continue to
progress ARX788 and the rest of our clinical development
pipeline.”
Edward Hu has more than 25 years’ experience in the
pharmaceutical industry. Mr. Hu currently serves as the Global
Chief Investment Officer, as an executive director, and as the Vice
Chairman of WuXi AppTec Co., Ltd., positions he has held since May
2020. Previously, Mr. Hu served as the Co-Chief Executive Officer
of WuXi AppTec Co., Ltd from August 2018 to May 2020, Chief
Financial Officer and Chief Investment Officer of WuXi AppTec Co.,
Ltd from April 2014 to August 2018, Chief Operating Officer and
Chief Financial Officer of WuXi AppTec Co., Ltd from February 2009
to April 2014, and Chief Operating Officer of WuXi AppTec Co., Ltd
from August 2007 to February 2009. Mr. Hu serves as a non-executive
director of CANbridge Pharmaceuticals, Inc., a position he has held
since July 2022 and also served as a non-executive director of WuXi
Biologics (Cayman) Inc. from February 2014 to June 2021 and as a
director of Viela Bio Inc. from May 2018 to March 2021. Mr. Hu
holds an MBA and an MS in chemistry from Carnegie Mellon
University, and a bachelor’s degree in physics from Zhejiang
University.
Kate Hermans has more than 20 years’ experience in the
pharmaceutical and healthtech industries. Currently, she is the
Chief Executive Officer of Hermans International LLC, a commercial
and investment advisory firm she founded in 2012 for startup and
early-stage enterprises. Previously, Ms. Hermans served as an
investor and Chief Business Officer (Pharma) for 83bar Inc., from
December 2018 to July 2021. She served as Vice President, Marketing
at Radius Health, Inc. from March 2017 to April 2018. Prior to her
time at Radius Health, Inc., Ms. Hermans held commercial and
operations executive leadership roles at Bristol Myers Squibb,
Pfizer/Wyeth Pharmaceuticals, and the Intel Corporation, working in
the U.S., China, Africa, and globally. Ms. Hermans is a Board
Director on the Advisory Board of Clue and serves on the Board of
Mid-Atlantic Diamond Ventures. Ms. Hermans is also a member of the
Healthcare Executive Review Committee for Ben Franklin Tech
Partners, a member of the Board of Directors for the Alzheimer’s
Association, Delaware Valley Chapter, and the Advisory Board of the
Women’s Resource Center. Ms. Hermans earned a Master of
International Management degree from The Thunderbird School of
Global Management and a B.A. in International Relations from
Wheaton College, MA.
About Ambrx Biopharma Inc. (Ambrx)
Ambrx is a clinical stage biopharmaceutical company using an
expanded genetic code technology platform to discover and develop
Engineered Precision Biologics. These include next generation
antibody drug conjugates (ADCs), bispecifics, targeted
immuno-oncology therapies, novel cytokines to modulate the immune
system, and long-acting therapeutic peptides for metabolic and
cardiovascular disease. Ambrx is advancing a robust portfolio of
clinical and preclinical programs designed to optimize efficacy,
safety and ease of use, in multiple therapeutic areas, including
its lead product candidate ARX788. In addition, Ambrx has clinical
collaborations with multiple partners, for drug candidates
generated using Ambrx technology. For more information, please
visit www.ambrx.com.
Forward-Looking Statements
This press release includes certain “forward-looking statements”
intended to qualify for the “safe harbor” from liability
established by the Private Securities Litigation Reform Act of
1995, as amended. Forward-looking statements may be identified by
the words “anticipate,” believe,” “estimate,” “expect,” “intend,”
“plan,” “project,” “may,” “will,” “could,” “should,” “seek,”
“potential” and similar expressions, and include, without
limitation, express or implied statements regarding Ambrx’s beliefs
and expectations regarding the advancement and potential benefits
of its product candidates, clinical development and strategic plans
and Mr. Hu’s and Ms. Hermans’ anticipated contributions.
Forward-looking statements are based on Ambrx’s current
expectations and are subject to inherent uncertainties, risks and
assumptions that are difficult to predict. Factors that could cause
actual results to differ include, but are not limited to, those
risks and uncertainties associated with: the continuing impact of
the COVID-19 pandemic and other public health-related risks and
events on Ambrx’s business, operations, strategy, goals and
anticipated milestones; Ambrx’s ability to execute on its strategy
including with respect to the timing of its R&D efforts,
initiation of clinical trials and other anticipated milestones;
risks associated with development of novel therapeutics, including
potential delays in clinical trials and regulatory submissions and
the fact that future clinical trial results may not be consistent
with preliminary results or results from prior preclinical studies
or clinical trials; Ambrx’s ability to fund operations as
anticipated; and the additional risks and uncertainties set forth
more fully under the caption “Risk Factors” in Ambrx’s Annual
Report on Form 20-F filed with the United States Securities and
Exchange Commission (SEC) on April 26, 2022, and elsewhere in
Ambrx’s filings and reports with the SEC. Forward-looking
statements contained in this press release are made as of this
date, and Ambrx undertakes no duty to publicly update or revise any
forward looking statements, whether as a result of new information,
future events or otherwise, except as may be required under
applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220705005732/en/
INVESTORS Laurence Watts Managing Director Gilmartin Group, LLC.
619-916-7620 ir@ambrx.com
MEDIA media@ambrx.com
Ambrx Biopharma (NYSE:AMAM)
Historical Stock Chart
Von Feb 2024 bis Mär 2024
Ambrx Biopharma (NYSE:AMAM)
Historical Stock Chart
Von Mär 2023 bis Mär 2024